CTDH News and Press, Ctd Holdings Inc From 08/15/19

CTD presentation to take place at the National Niemann-Pick Disease Foundation Conference August 16, 2019 CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today poste...

CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biopharmaceutical company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that it has filed supporting data for its patent application titled “Methods for Treating Alzheim...

CTD Holdings, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced the Company’s sponsorship and participation of the annual gathering of families supported by that Nat...

CTD Holdings, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that the Company’s Scientific Advisory Board endorsed Alzheimer’s Disease as the companyȁ...

CTD Holdings, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that the Company had obtained a Right of Reference letter to IND 138423. The IND is for “Expanded Acc...

CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced the appointment of Mr. Michael Lisjak as Global Head of Regulatory Affairs and Senior Vice President for Bus...

ALACHUA, FL, June 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that it has submitted its applicat...

Favorable risk/benefit analysis outlined in report to FDA ALACHUA, FL / ACCESSWIRE / June 10, 2019 / CTD Holdings, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced t...

ALACHUA, FL / ACCESSWIRE / May 31, 2019 / CTD Holdings, Inc. (OTCQB: CTDH)("CTD" or the "Company"), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that it closed its previously announced p...

ALACHUA, FL / ACCESSWIRE / May 30, 2019 / CTD Holdings, Inc. (OTCQB: CTDH) (''CTD'' or the ''Company''), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announces a private placement to raise approximately...